The NeoFox phase II trial aimed to assess the feasibility and efficacy of a neo-adjuvant treatment regimen in pts with stage II/III colon cancer. The Ad hoc observations suggested Foxy-5 impairs invasion and induces downstaging in stage II/III colon cancer. Patients (pts) with normal or near normal WNT5A expression in their breast cancer, […]...
ESMO-GI 2024
Coverage of ESMO Gastrointestinal Cancers Congress 2024
Jun 26
-Jun 29, 2024